Navigation Links
Genesis Pharmaceuticals Files Counter Claims
Date:10/31/2008

LAIYANG, China, Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, was granted leave by the American Arbitration Association ("AAA") to amend its counterclaims and add claims for defamation and breach of contract in a contractual dispute with Capital Research Group Partners, Inc. and Capital Research Group, Inc. ("CRG&P"). The hearing date for the arbitration is set for December 1, 2008 in the AAA offices in Miami, Florida.

CRG&P recently issued a press release that Genesis alleges included numerous false and defamatory statements about Genesis and Genesis' officers and directors.

"We believe that CRG&P made false statements against us in an attempt to damage our Company's reputation. We plan to vigorously pursue our new counterclaims in the upcoming arbitration," stated Mr. Wubo Cao, Chairman and CEO of Genesis Pharmaceuticals Enterprises.

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a pharmaceutical company in China producing western and Chinese herbal-based medical drugs in tablet, capsule, and granule form.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Genesis Pharmaceuticals Enterprises, Inc.

Ms. Elsa Sung, CFO

Tel: +1-954-727-8435

Email: elsasung@jiangbo.com

Web: http://www.genesispharmaceuticals.com

CCG Investor Relations, Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pathway links inflammation, angiogenesis and breast cancer
2. EURYI project to understand how the brain wires during embryogenesis
3. DNA damage response confers a barrier for viral tumorigenesis
4. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
5. The genetics of MLL leukemogenesis
6. Genesis Technology Group Retains CCG Elite
7. Researchers chart the genetic mechanisms behind the genesis of fat cells
8. Tissue Genesis Signs Exclusive Distribution and License Agreement with SpineSmith
9. ThermoGenesis Corp. Reports First Quarter 2008 Results
10. Cardiogenesis Receives FDA Approval for PEARL 5.0 Robotic Hand Piece
11. Genesis Pharmaceuticals Announces Results for The First Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The TouchPoint Solution’s ... the Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch about the ... , Project Entrepreneur’s second annual venture competition ignites bold ideas by providing women access ...
(Date:3/27/2017)... , ... March 27, 2017 , ... The Case Management ... of Directors on June 30, 2017. CMSA’s membership has elected their upcoming President-Elect, ... our current Military Advisory position, a new VA Advisory position has also been added ...
(Date:3/27/2017)... Birmingham, Clarkston, and Lake Orion, Michigan (PRWEB) , ... ... ... can affect weight loss results. The comprehensive weight management program at Women’s ... begins with an initial evaluation and physical exam. The specialists at ...
(Date:3/27/2017)... ... March 27, 2017 , ... Kwalu, a leading provider of ... row; they are the recipient of the prestigious “Best Overall Design Strategy in ... at Design Connections 2017. Top A&D professionals from leading firms, furniture manufacturers and ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer Society , ... more than 95%. Once the cancer spreads to other organs, bones, or lymph nodes, ... how to avoid this latter group, tune in to Lifestyle Magazine on ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
(Date:3/27/2017)... March 27, 2017  BERG, a biopharmaceutical ... biological research approach, today announced that the ... discovery of new data using a cold-induced ... fat metabolism. Joslin Diabetes Center led the ... platform for analysis of samples.  The findings ...
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
Breaking Medicine Technology: